1.
Sotrovimab restores neutralisation against current Omicron subvariants in patients with blood cancer
Cancer cell
; 2023.
Article
in English
| EuropePMC | ID: covidwho-2305848
ABSTRACT
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
2.
Lancet
; 2022 Oct 06.
Article
in English
| MEDLINE | ID: covidwho-2062001